echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > FDA approves LENVIMA-KEYTRUDA combination therapy for specific types of endometrial cancer

    FDA approves LENVIMA-KEYTRUDA combination therapy for specific types of endometrial cancer

    • Last Update: 2020-06-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    The Orbis project provides a framework for its international partners to submit and review cancer drugs simultaneouslyUnder the program, the FDA, the Australian Drug Administration (TGA) and Health Canada jointly reviewed applications for two cancer drugs, allowing simultaneous decisions in all three countriesthe approval is based on data from study 111/KEYNON-146, a phase II, multi-group, open-label, open-label, single-group trial that included 108 patients with metastatic endometrial cancer who had progression after at least one systemic treatment in any caseIn 94 patients without MSI-H or dMMR, LENVIMA-KEYTRUDA combined therapy showed ANR of 38.3% (95% CI, 29-49), a full response rate of 10.6% (n-10) and a partial response rate of 27.7% (n-26)In patients who were identified as having a reaction through an independent review (n-36), the median DOR (ranging from 1.2 to 33.1 plus months) was not reached at the data deadline; The most common adverse reactions to LENVIMA-KEYTRUDA combination therapy were fatigue, musculoskeletal pain, high blood pressure, diarrhea, loss of appetite, hypothyroidism, nausea, stomatitis, vomiting, weight loss, abdominal pain, headache, constipation, urinary tract infections, vocal disorders, bleeding events, hypomatoemia, hand and foot syndrome, dyspnea, coughs and rashesNote: Cut in the original text
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.